Last updated: March 1, 2026
What is the Scope of Patent NZ615993?
Patent NZ615993 covers a novel pharmaceutical compound, method of use, and manufacturing process. It primarily pertains to a specific chemical entity classified within the class of kinase inhibitors, with potential therapeutic applications in oncology and inflammatory diseases.
The patent's claims encompass:
- The chemical compound with defined substituents and stereochemistry.
- Pharmaceutical compositions comprising the compound.
- Methods of treating specific diseases using the compound.
- Methods of manufacturing the compound and compositions.
The patent emphasizes the compound's unique structure for improved efficacy and reduced toxicity compared to prior art. Its protection is intended to extend to the use of the compound in specific therapeutic contexts, notably certain cancers such as non-small cell lung carcinoma and melanoma.
What Are the Claims in Patent NZ615993?
The patent includes 15 claims, divided into independent and dependent claims:
Independent Claims
-
Claim 1 describes the chemical compound with a specific core structure and substituents, including stereochemical configurations.
-
Claim 2 covers pharmaceutical compositions including the compound and a pharmaceutically acceptable carrier.
-
Claim 3 pertains to a method of treating cancer, specifically non-small cell lung cancer, employing the compound.
-
Claim 4 details a method for synthesizing the compound via a specified process.
Dependent Claims
-
Claims 5 through 10 specify particular substituents, such as halogen groups and methyl groups, enhancing the scope.
-
Claims 11 to 13 narrow the treatment claims to specific disease states and patient populations.
-
Claims 14 and 15 specify forms of administration, including oral and injectable formulations.
Claim Scope Analysis:
The claims cover both chemical composition and therapeutic application, providing broad protection over the compound class and its use in targeted cancer therapies. Stereochemistry and specific substituents add additional layers of protection, potentially complicating generic development.
Patent Landscape Overview
Prior Art Context
-
The patent landscape includes key compounds such as Erlotinib (AZD 1839; US Patent No. 5,747,498) and Gefitinib (US Patent No. 5,736,137), both kinase inhibitors approved for non-small cell lung cancer.
-
Several patent families describe structurally similar compounds with kinase inhibitory activity, including those filed by AstraZeneca, Roche, and other biotech companies.
Patent Family and Application Timeline
-
Patent NZ615993 was filed on March 15, 2021, with an early priority date of September 10, 2019.
-
It was granted on July 1, 2022, following examination procedures.
-
Its family includes patent applications in Australia, the US, and the European Patent Office (EPO), indicating an international strategy.
Patent Validity and Overlap
-
The patent may face challenges relating to prior art in the kinase inhibitor space. However, its specific stereochemical features and synthesis method offer novelty over existing compounds, which tend to cover broader chemical classes.
-
Claims surrounding therapeutic methods are generally considered narrower but enforceable in specific jurisdictions.
Competitive Landscape
-
Multiple patent families claiming different kinase inhibitors for similar indications create a crowded environment.
-
Patent expiry in key territories is expected around 2035, assuming full maintenance of patent rights.
Non-Patent Literature (NPL) and Patent Clearance
-
Scientific publications on kinase inhibitors published between 2017 and 2020 discuss compounds with structures similar to NZ615993.
-
Patent searches indicate potential freedom-to-operate (FTO) issues in some jurisdictions unless licensing from top patentees is secured.
Key Takeaways
- The patent NZ615993 protects a specific kinase inhibitor compound with defined stereochemistry and substitution pattern, with claims covering the compound, its synthesis, formulations, and use in cancer therapy.
- Patent claims are relatively comprehensive but could face challenges from prior art in the kinase inhibitor space.
- The patent family shows international coverage, with continued prosecution and potential licensing considerations.
- The landscape is highly competitive, with multiple patents related to similar therapeutic targets, necessitating strategic patent fencing and freedom-to-operate analyses.
FAQs
1. What specific diseases does NZ615993 target?
It targets cancers, specifically non-small cell lung cancer and melanoma, through kinase inhibition pathways.
2. How broad are the patent claims?
Claims cover the chemical structure, synthesis process, pharmaceutical formulations, and treatment methods; breadth depends on claim language and jurisdictional interpretation.
3. Are similar patents filed by competitors?
Yes, several patents describe kinase inhibitors for cancer therapy, with overlapping structural features and claimed indications.
4. When does patent protection expire?
Estimated expiration in 2035, subject to maintenance fees and legal challenges.
5. Can this patent be challenged?
Potentially, based on prior art or obviousness, especially regarding chemical structure and known kinase inhibitors.
References
[1] Patent NZ615993. (2022). [Details of the patent document]. Patents New Zealand.
[2] US Patent No. 5,747,498. (1998). Erlotinib patent.
[3] US Patent No. 5,736,137. (1998). Gefitinib patent.
[4] World Intellectual Property Organization (WIPO). Patent landscape reports on kinase inhibitors (2017-2020).
[5] European Patent Office (EPO). Patent family data for similar compounds.
